Ecoza is a drug owned by Resilia Pharmaceuticals Inc. It is protected by 2 US drug patents filed from 2013 to 2018. Out of these, 1 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 08, 2031. Details of Ecoza's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10071054 | Econazole composition and methods of treatment therewith |
Aug, 2031
(6 years from now) | Active |
| US5993830 | Cosmetic skin preparation |
Jan, 2018
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ecoza's patents.
Latest Legal Activities on Ecoza's Patents
Given below is the list of recent legal activities going on the following patents of Ecoza.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Mar, 2022 | US10071054 |
| Mail O.P. Petition Decision | 27 Sep, 2018 | US10071054 |
| Electronic Review Critical | 27 Sep, 2018 | US10071054 |
| Email Notification Critical | 27 Sep, 2018 | US10071054 |
| Mail-Petition Decision - Granted | 26 Sep, 2018 | US10071054 |
| Petition Decision - Granted Critical | 25 Sep, 2018 | US10071054 |
| O.P. Petition Decision | 20 Sep, 2018 | US10071054 |
| Patent Issue Date Used in PTA Calculation Critical | 11 Sep, 2018 | US10071054 |
| Recordation of Patent Grant Mailed Critical | 11 Sep, 2018 | US10071054 |
| Email Notification Critical | 24 Aug, 2018 | US10071054 |
FDA has granted several exclusivities to Ecoza. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Ecoza, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Ecoza.
Exclusivity Information
Ecoza holds 1 exclusivities. All of its exclusivities have expired in 2016. Details of Ecoza's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 24, 2016 |
US patents provide insights into the exclusivity only within the United States, but Ecoza is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ecoza's family patents as well as insights into ongoing legal events on those patents.
Ecoza's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ecoza's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 08, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ecoza Generic API suppliers:
Econazole Nitrate is the generic name for the brand Ecoza. 5 different companies have already filed for the generic of Ecoza, with Aurobindo Pharma Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ecoza's generic
About Ecoza
Ecoza is a drug owned by Resilia Pharmaceuticals Inc. It is used for treating skin conditions. Ecoza uses Econazole Nitrate as an active ingredient. Ecoza was launched by Resilia Pharms in 2013.
Approval Date:
Ecoza was approved by FDA for market use on 24 October, 2013.
Active Ingredient:
Ecoza uses Econazole Nitrate as the active ingredient. Check out other Drugs and Companies using Econazole Nitrate ingredient
Treatment:
Ecoza is used for treating skin conditions.
Dosage:
Ecoza is available in aerosol, foam form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% | AEROSOL, FOAM | Prescription | TOPICAL |